The Company collaborates with Jiangsu Yike Regenerative Medicine Technology Co., Ltd. Yike Medical Center is a duly licensed medical institution qualified to conduct stem-cell-related activities and is registered in China as an authorized institution for stem cell clinical research.
Core business areas include:
● Stem Cell Clinical Treatment Services: A comprehensive testing and treatment system that provides stem-cell-based adjunctive therapies for patients with chronic conditions such as diabetes and hypertension.
● Anti-Aging Products: Including NAD+, stem cells, immune cells, cellular-level anti-aging solutions, and functional restoration therapies.
● Premium Medical Aesthetics: Including stem-cell-based aesthetic treatments, systemic detoxification and cleansing, non-invasive facial restoration, external anti-aging treatments, and skin rejuvenation.
● The Company has established collaborative relationships with major medical institutions across China to provide stem-cell-based adjunctive therapies for patients with chronic conditions, including diabetes and hypertension, as well as for cancer patients.
B. Comprehensive Health and Health Management
The Company focuses on the fast-growing microbiome health sector. Guided by the philosophy of “Cultivating a Healthy Microbiome, Sharing Lifelong Wellness,” it is developing an integrated “testing + products + services” ecosystem that provides microbiome health management throughout the full lifecycle.
The global microbiome health market was valued at tens of billions of U.S. dollars in 2025. The North American market is estimated at nearly US$20 billion, while the Asian market exceeds US$50 billion, with annual growth of more than 10%. Microbiome health represents an emerging growth driver within the broader health and wellness industry.
Key Product Advantages
● Technology and Product Barriers to Entry
● Deep Industry–Academic–Research Integration: The Company has obtained authorization to use four patented probiotic strains developed by Jiangnan University, including a patented strain targeting Helicobacter pylori. In collaboration with Guangzhou Pharmaceutical Holdings and Quantum Hi-Tech (an investee of the UK-based Tate & Lyle Group), the Company develops high-potential products and has established a synbiotic product portfolio combining probiotics, prebiotics, and postbiotics. This approach addresses common challenges such as low viable-cell survival rates and inconsistent efficacy.
● Precision Product Portfolio: Four major product lines address Helicobacter pylori, gastrointestinal health, women’s intimate health, and weight management. Combined with digital testing technologies, including biochips, these solutions enable individualized interventions and have achieved a repurchase rate exceeding 70%.
● Leadership in Technology Innovation: The Company is developing advanced technologies such as postbiotics, which offer greater stability and do not require refrigeration, and microbiota transplantation. These initiatives position the Company across the full precision-health value chain of testing, analysis, intervention, and management.
● Innovative Business Model
● Collaborative Social New-Retail Model: The “platform + retail locations + microbiome nutritionists” model integrates online customer acquisition, empowers physical retail locations, and develops professional teams, creating shared value for the brand, business partners, and consumers.
● Private-Domain Engagement and Offline Service Loop: A digital system integrates data monitoring, program follow-up, nutritionist consultations, and health education, enabling seamless online-to-offline service delivery and increasing lifetime customer value.
● Full-Cycle Health Management
● Routine Health Maintenance (30–90 Days)
● Gastrointestinal health products and complimentary testing, subsequently expanding into weight management, women’s intimate health, immune support, chronic disease prevention, and products based on the traditional concept that food and medicine share a common origin.
● Precision Health Management (90–180 Days)
● Microbiome testing combined with personalized product programs replaces standardized, one-size-fits-all approaches with targeted interventions.
● Professional Health Management
● Precision health management, chronic disease prevention, and microbiota transplantation provide an entry point into premium, medical-grade services while establishing dual competitive barriers through technology and service capabilities.